Soluble HLA class I, HLA class II, and Fas ligand in blood components: A possible key to explain the immunomodulatory effects of allogeneic blood transfusions

Blood

Volumn 93, Issue 5, 1999, Pages 1770-1777

  Ghio, M ^b   Contini, P ^b   Mazzei, C ^b   Brenci, S ^b   Barberis, G ^b   Filaci, G ^b   Indiveri, F ^b   Puppo, F ^a  

^a DiMI Viale Benedetto XV   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; FRESH FROZEN PLASMA; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

APOPTOSIS; ARTICLE; BLOOD COMPONENT; BLOOD STORAGE; BLOOD TRANSFUSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ERYTHROCYTE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; THROMBOCYTE; TRANSPLANTATION;

EID: 0033105729     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.5.1770.405a14_1770_1777     Document Type: Article

References (77)

1. Billingham RE, Brent L, Medawar PB: 'Actively acquired tolerance'of foreign cells. Nature 172:603, 1953
2. Opelz G, Mickey MR, Terasaki P: Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 5:253, 1973
3. Persijn GG, Cohen B, Lansbergen Q, Van Rood JJ: Retrospective and prospective studies on the effect of blood transfusions in renal transplantation in The Netherlands. Transplantation 28:396, 1979
4. Jonker M, Persijn GG, Parlevliet J, Frederiks E, Van Rood JJ: The influence of previous immunization on skin graft survival. Transplantation 27:250, 1979
5. Van Rood JJ, Claas F: The influence of allogeneic cells on the human T and B cell repertoire. Science 248:1388, 1990
6. Van Rood JJ, Claas F: Impact of histocompatibility testing, or the Yin-Yang of transplantation, in Tilney NL, Strom TB, Paul LC (eds): Transplantation Biology: Cellular and Molecular Aspects, Philadelphia, PA, Lippincott-Raven, 1996, p 341
7. Dzik S, Blajchman MA, Blumberg N, Kirkley SA, Heal JM, Wood K: Current research on the immunomodulatory effect of allogeneic blood transfusion. Vox Sang 70:187, 1996
8. Blajchman MA: Allogeneic blood transfusions, immunomodulation, and postoperative bacterial infection: Do we have the answers yet. Transfusion 37:121, 1997
9. Vamvakas EC, Moore SB: Blood transfusion and postoperative septic complications. Transfusion 34:714, 1994
10. Lapierre V, Aupérin A, Tiberghien P: Transfusion-induced immunomodulation following cancer surgery: Fact or fiction? J Natl Cancer Inst 90:573, 1998
11. Houbiers JG, van de Velde CJ, van de Watering LM, Hermans J, Schreuder S, Bijnen AB, Pahlplatz P, Eeftinck Schattenkerk M, Wobbes T, de Vries JE, Klementschitsch P, van de Maas AH, Brand A: Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: A prospective study. Transfusion 37:126, 1997
12. Busch OR, Hop WC, Hoynck van Papendrecht MA, Marquet RL, Jeekel J: Blood transfusions and prognosis in colorectal cancer. N Engl J Med 328:1372, 1993
13. van de Watering LMG, Hermans J, Houbiers JG, van den Broek PJ, Bouter H, Boer F, Harvey MS, Huysmans HA, Brand A: Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery. A randomized clinical trial. Circulation 97:562, 1998
14. Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S: Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res 44:4679, 1984
15. Lee JS: Regulation of HLA class II gene expression, in Dupont B (ed): Immunobiology of HLA. New York, NY, Springer-Verlag, 1987, p 49
16. Van Rood JJ, van Leeuwen A, van Santen MCT: Anti HL-A2 inhibitor in normal human serum. Nature 226:366, 1970
17. Charlton RK, Zmijewski CM: Soluble HL-A7 antigen: localization in die β-lipoprotein fraction of human serum. Science 170:636, 1970
18. Allison JP, Pellegrino MA, Ferrone S, Callahan GN, Reisfeld RA: Biologic and chemical characterization of HLA antigens in human serum. J Immunol 118:1004, 1977
19. Dobbe LME, Stam NJ, Neefjes JJ, Giphart MJ: Biochemical complexity of serum HLA class I molecules. Immunogenetics 27:203, 1988
20. Krangel MS: Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway. J Exp Med 163:1173, 1986
21. Krangel MS: Two forms of HLA Class I molecules in human plasma. Hum Immunol 20:155, 1987
22. Wilson BS, Indiveri F, Pellegrino MA, Ferrone S: Production and characterization of DR xenoantisera: Use for detection of serum DR antigens. J Immunol 122:1967, 1979
23. Puppo F, Brenci S, Lanza L, Bosco O, Imro MA, Scudeletti M, Indiveri F, Ferrone S: Increased level of serum HLA Class I antigens in HIV infection. Correlation with disease progression. Hum Immunol 40:259, 1994
24. Hagihara M, Shimura T, Yamamoto K, Sujirachato K, Tsuji S, Yamamura M, Tsuji K: Clinical significance of serum soluble HLA class I antigens in systemic lupus erythematosus. Tokai J Exp Clin Med 18:61, 1993
25. Zavazava N, Böttcher H, Müller-Ruchholtz W: Soluble MHC class 1 antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. Tissue Antigens 42:20, 1993
26. Rhynes KV, McDonald JC, Gelder FB, Aultman DF, Hayes JM, McMillan RW, Mancini MC: Soluble HLA class I in the serum of transplant recipients. Ann Surg 217:485, 1993
27. Davies H, Pollard SG, Calne RY: Soluble HLA antigens in the circulation of liver graft recipients. Transplantation 47:524, 1989
28. Puppo F, Pellicci R, Brenci S, Nocera A, Morelli A, Dardano G, Bertocchi M, Antonucci A, Ohio M, Scudeletti M, Barocci S, Valente U, Indiveri F: HLA Class-1-soluble antigen serum levels in liver transplantation. A predictor marker of acute rejection. Hum Immunol 40:166, 1994
29. DeVito-Haynes LD, Jankowska-Gan E, Sollinger HW, Knechtle SJ, Burlingham WJ: Monitoring of kidney and simultaneous pancreaskidney transplantation rejection by release of donor-specific, soluble HLA class I. Hum Immunol 40:191, 1994
30. Pollard SG, Davies HffS, Calne RY: Peroperative appearance of serum class I antigen during liver transplantation. Transplantation 49:659, 1990
31. Westhoff U, Doxiadis I, Beelen DW, Schaefer UW, Grosse-Wilde H: Soluble HLA class I concentrations and GVHD after allogeneic marrow transplantation. Transplantation 48:890, 1989
32. Puppo F, Brenci S, Ghio M, Bignardi D, Contini P, Bacigalupo A, Van Lint MT, Scudeletti M, Ferrone S, Indiveri F: Serum HLA class I antigen levels in allogeneic bone marrow transplantation: A possible marker of acute GVHD. Bone Marrow Transplant 17:753, 1996
33. Westhoff U, Grosse Wilde H: Soluble HLA class I and class II concentrations in factor VIII and PCC preparations. Vox Sang 68:73, 1995
34. Grosse-Wilde H, Blasczyk R, Westhoff U: Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens 39:74, 1992
35. Blasczyk R, Westhoff U, Grosse-Wilde H: Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 341:789, 1993
36. Santoso S, Kiefel V, Volz H, Mueller-Eckhardt C: Quantitation of soluble HLA class I antigen in albumin and immunoglobulin preparations for intravenous use by solid-phase immunoassay. Vox Sang 62:29, 1992
37. Hausmann R, Zavazava N, Steinmann J, Müller-Ruchholtz W: Interaction of papain-digested HLA class I molecules with human alloreactive cytotoxic T lymphocytes (CTL). Clin Exp Immunol 91:183, 1993
38. 2 domain of HLA-A2. Nature 325:625, 1987
39. Schneck J, Lee Maloy W, Coligan JE, Margulies DH: Inhibition of an allospecific T cell hybridoma by soluble class I proteins: estimation of the affinity of a T cell receptor for MHC. Cell 56:47, 1989
40. Puppo F, Brenci S, Montinaro E, Lanza L, Contini P, Scudeletti M, Indiveri F: Inhibition of alloreactive cytotoxic T cell activity by HIV-positive sera: Potential role of circulating soluble HLA Class I molecules. AIDS Res Hum Retrovir 10:1061, 1994
41. + lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest 93:1361, 1994
42. Zavazava N, Krönke M: Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nature Med 2:1005, 1996
43. Sayegh MH, Carpenter CB: Role of indirect allorecognition in allograft rejection. Int Rev Immunol 13:221, 1996
44. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S: Expression of the Fas ligand in cells of T cell lineage. J Immunol 154:3806, 1995
45. Conrad Liles W, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ: Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils. J Exp Med 429, 1996
46. Nagata S: Fas and Fas ligand: A death factor and its receptor. Adv Immunol 57:129, 1994
47. van Parijs L, Abbas AK: Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol 8:355, 1996
48. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S: Fas ligand in human serum. Nature Med 2:317, 1996
49. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler AZ: Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens: New tools for genetic analysis. Cell 14:9, 1978
50. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S: Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 87:284, 1991
51. Pellegrino MA, Ng AK, Russo C, Ferrone S: Heterogeneous distribution of determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation 34:18, 1982
52. Quaranta V, Tanigaki N, Ferrone S: Distribution of antigenic determinants recognized by three monoclonal antibodies (Q2/70, Q5/6 and Q5/13) on human Ia-like alloantigens and on their subunits. Immunogenetics 12:175, 1981
53. Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, Ferrone S: Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods 161:239, 1993
54. Coligan JE, KruisbeekAM, Margulies DH, Shevach EM, Strober W: Flow cytometry. Curr Protocols Immunol 1:5.3.6, 1998
55. 125I-labelled human growth hormone of high specific radioactivity. Biochem J 89:11, 1963
56. Böyum A: Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 21:77, 1968 (suppl 97)
57. Comuzio S, Puppo F, Ruzzenenti R, Orlandini A, Grillo F, Brenci S, Lanza L, Scudeletti M, Indiveri F: Simple ELISA method for the evaluation of soluble HLA class I antigens in human serum. J Lab Clin Anal 5:278, 1991
58. Filaci G, Contini P, Brenci S, Lanza L, Scudeletti M, Indiveri F, Puppo F: Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. Tissue Antigens 46:117, 1995
59. Laemmli UK: Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227:680, 1970
60. Towbin H, Staehelin T, Gordon J: Electrophoresis transfer proteins from polyacrylamide gels to nitrocellulose sheets. Procedure and some applications. Proc Natl Acad Sci USA 76:4350, 1979
61. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271, 1991
62. Kao KJ: Plasma and platelet HLA in normal individuals: Quantitation by competitive enzyme-linked immunoassay. Blood 70: 282, 1987
63. Liebert M, Aster RH: Expression of HLA-B12 on platelets, on lymphocytes and in serum: A quantitative study. Tissue Antigens 9:199, 1977
64. Lalezari P, Driscoll AM: Ability of thrombocytes to acquire HLA specificity from plasma. Blood 59:167, 1982
65. Everett ET, Kao KJ, Scornik JC: Class I HLA molecules on human erythrocytes. Quantitation and transfusion effects. Transplantation 44:123, 1987
66. Aster RH, Miskovich BM, Rosley GE: Histocompatibility antigens in human plasma. Localization to the HLD-3 lipoprotein fraction. Transplantation 16:205, 1973
67. Kao KJ, Scornik JC, Riley WJ, McQueen CF: Association between HLA phenotype and HLA concentration in plasma or platelets. Hum Immunol 21:115, 1998
68. Kao KJ: Stability of platelet and plasma HLA concentrations in healthy adults or random-donor pletelet concentrastes. Transfusion 29:328, 1989
69. Sherman L, Chattopadhyay S: The molecular basis of allorecognition. Annu Rev Immunol 11:385, 1993
70. Kägi D, Ledermann B, Zinkernagel RM, Hengartner H: Lymphocyte-mediated cytotoxicity in vitro and in vivo: Mechanisms and significance. Immunol Rev 146:95, 1998
71. Klüter H, Schlenke P, Müller-Steinhardt M, Paulsen M, Kirchner H: Impact of buffy coat storage on the generation of inflammatory cytokines and platelet activation. Transfusion 37:362, 1998
72. Shanwell A, Kristiansson M, Remberger M, Ringdén O: Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion 37:678, 1998
73. 73; Mincheff M: Changes in donor leukocytes during blood storage. Implications on post-transfusion immunomodulation and transfusion-associated GVHD. Vox Sang 74:189, 1998 (suppl 2)
74. Dzik S, Szuflad P, Eaves S: HLA antigens on leukocyte fragments and plasma proteins. Prestorage leukoreduction by filtration. Vox Sang 66:104, 1998
75. 3 domain of HLA-A2. Nature 345:41, 1990
76. + lymphocytes by Fas(CD95)/Fas-ligand interactions. Eur J Immunogenet 24:6, 1997 (suppl 1, abstr 10)
77. Ju ST, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444, 1995